Business
Quantum BioPharma Announces Private Placement of 12 Class A Multiple Voting Shares at a Price of $50 Per Share
TORONTO, June 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it is completing a non-brokered private placement of class A multiple voting shares (“MVS”) at a price of $50 per MVS, for aggregate gross proceeds of up to $600 (the “Offering”). The Company expects that the entirety of
About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B
[{"type":"image","alt":"Quantum BioPharma","displaySize":"","headline":null,"caption":"Quantum BioPharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/afa2918fb4040d1890576b67ae88dcb3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XbswrLbZoNoT5isbohZcMw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/afa2918fb4040d1890576b67ae88dcb3","width":300,"height":87}},"lazy":false},{"type":"text","content":"TORONTO, June 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it is completing a non-brokered private placement of class A multiple voting shares (“MVS”) at a price of $50 per MVS, for aggregate gross proceeds of up to $600 (the “Offering”). The Company expects that the entirety of the Offering will be subscribed for by the existing holders of MVS.","length":587,"tagName":"p"},{"type":"text","content":"All securities issued pursuant to the Offering are subject to a statutory hold period of four months plus a day from issuance in accordance with applicable securities laws of Canada. The Company intends to use the proceeds of the Offering for general working capital purposes.","length":276,"tagName":"p"},{"type":"text","content":"MI 61-101 Disclosure","length":20,"tagName":"p"},{"type":"text","content":"It is anticipated that the Offering will be fully subscribed by Xorax Family Trust (“Xorax”), a trust of which Zeeshan Saeed, the Chief Executive Officer and Co-Chairman of the Company is a beneficiary, and Fortius Research and Trading Corp. (“Fortius”), a corporation of which Anthony Durkacz, a director of the Company is a director, purchased all the MVS issued pursuant to the Offering. The participation by such insiders is considered a “related-party transaction” within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company has relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in respectively, sections 5.5(a) and 5.7(1)(a) of MI 61-101...
More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B